ReviewCurrent opinion in HIV and AIDS2011
Myeloid dendritic cells in HIV-1 infection.
Review in Current opinion in HIV and AIDS, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Serum matters: human platelet lysate enables physiological modeling of HIV-1 infection in dendritic cells.Frontiers in immunology · 2025Article
- FcRn regulates antigen presentation in dendritic cells downstream of DEC205-targeted vaccines.NPJ vaccines · 2024Article
- The causal relationship between immune cells and Sjögren's syndrome: a univariate, multivariate, bidirectional Mendelian randomized study.Frontiers in medicine · 2024Article
- The Role of Dendritic Cells During Infections Caused by Highly Prevalent Viruses.Frontiers in immunology · 2020Review
- The Role of the BCL-2 Family of Proteins in HIV-1 Pathogenesis and Persistence.Clinical microbiology reviews · 2019Review
- Dendritic Cells, the Double Agent in the War Against HIV-1.Frontiers in immunology · 2019Review
- Myeloid Cells in Intact Human Cervical Explants Capture HIV and Can Transmit It to CD4 T Cells.Frontiers in immunology · 2018Article
- PolyICLC Exerts Pro- and Anti-HIV Effects on the DC-T Cell Milieu In Vitro and In Vivo.PloS one · 2016Article
- Retinoic acid imprints a mucosal-like phenotype on dendritic cells with an increased ability to fuel HIV-1 infection.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Article
- Article
- Review
- Kinetics of myeloid dendritic cell trafficking and activation: impact on progressive, nonprogressive and controlled SIV infections.PLoS pathogens · 2013Article
- Construction and immunological evaluation of dual cell surface display of HIV-1 gag and Salmonella enterica serovar Typhimurium FliC in Lactobacillus acidophilus for vaccine delivery.Clinical and vaccine immunology : CVI · 2012Article
- The role of HIV-1 Vpr in promoting the infection of nondividing cells and in cell cycle arrest.Current opinion in HIV and AIDS · 2012Review
- Natural Immunity to HIV: a delicate balance between strength and control.Clinical & developmental immunology · 2012Review
- Influence of dendritic cells on B-cell responses during HIV infection.Clinical & developmental immunology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewMyeloid dendritic cells (mDCs) are pivotal players in HIV-1 infection. They promote transmission and spread and at the same time are critical for recognizing HIV-1 and initiating immune responses to fight infection. Notably, their immunostimulatory capabilities can be harnessed to design better HIV-1 vaccines. In this review, advances in these areas of mDC-HIV-1 interactions are summarized. RECENT
findingsNew insights into HIV-1-induced dysfunction of mDCs and dysfunctional mDC effects on other cell types, as well as novel mechanisms of viral sensing by mDCs and their evasion by HIV-1, have been uncovered. These results emphasize the importance of mDCs in protection against HIV-1 infection. Targeting mDCs with vaccines and tailored adjuvants may improve the quality and anatomical location of elicited immune responses. SUMMARY: Understanding the multiplicity of HIV-1-dendritic cell interactions together with the numerous advances in targeted therapy and vaccination will help in the rational design of approaches to treat and block infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.